

Rebecca Kruse-Jarres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/740414/publications.pdf>

Version: 2024-02-01

25
papers

1,822
citations

840776

11
h-index

752698

20
g-index

26
all docs

26
docs citations

26
times ranked

1297
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment. <i>Haemophilia</i> , 2021, 27, e479-e483.	2.1	0
2	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 32-41.	3.8	14
3	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 21-31.	3.8	7
4	Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28474.	1.5	11
5	Emicizumab in Hemophilia A. <i>New England Journal of Medicine</i> , 2020, 382, 785-786.	27.0	4
6	Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). <i>Haemophilia</i> , 2019, 25, 382-391.	2.1	28
7	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. <i>Haemophilia</i> , 2019, 25, 213-220.	2.1	31
8	The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. <i>Haemophilia</i> , 2019, 25, 33-44.	2.1	63
9	How I treat type 2B von Willebrand disease. <i>Blood</i> , 2018, 131, 1292-1300.	1.4	40
10	Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. <i>Haemophilia</i> , 2018, 24, 921-929.	2.1	20
11	Serum 25-Hydroxyvitamin D and Diet Mediates Vaso-Occlusive Related Hospitalizations in Sickle-Cell Disease Patients. <i>Nutrients</i> , 2018, 10, 1384.	4.1	7
12	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. <i>New England Journal of Medicine</i> , 2018, 379, 811-822.	27.0	489
13	Acquired hemophilia <scp>A</scp>: Updated review of evidence and treatment guidance. <i>American Journal of Hematology</i> , 2017, 92, 695-705.	4.1	267
14	Emicizumab Prophylaxis in Hemophilia A with Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 809-818.	27.0	794
15	Identification and Basic Management of Bleeding Disorders in Adults. <i>Journal of the American Board of Family Medicine</i> , 2014, 27, 549-564.	1.5	20
16	Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction. <i>Blood</i> , 2013, 122, 1106-1106.	1.4	2
17	Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial. <i>Blood</i> , 2013, 122, 206-206.	1.4	1
18	Analysis Of Hemostatic Characteristics Using Thromboelastometry In Adults With Sickle Cell Disease And Controls. <i>Blood</i> , 2013, 122, 4766-4766.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience. Blood, 2012, 120, 1123-1123.	1.4	0
20	Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results.. Blood, 2012, 120, 2224-2224.	1.4	0
21	Reduced production of IFN- γ and LT- α is associated with successful prednisone therapy in patients with acquired hemophilia A: A pilot study. Thrombosis Research, 2011, 128, e86-e90.	1.7	3
22	Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A. Hematology American Society of Hematology Education Program, 2011, 2011, 407-412.	2.5	18
23	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. Blood, 2011, 118, 27-27.	1.4	2
24	Baseline Characteristics Associated with Vitamin D Deficiency in Sickle Cell Disease and the Effect of Vitamin D Replacement. Blood, 2011, 118, 2139-2139.	1.4	1
25	Vitamin D Deficiency In Pediatric Patients with Sickle Cell Disease Correlates with Reticulocytosis but Not with Clinical Disease Severity. Blood, 2010, 116, 4820-4820.	1.4	0